BNP Paribas Financial Markets
IMMX icon

BNP Paribas Financial Markets’s Immix Biopharma IMMX Stock Holding History

BNP Paribas Financial Markets’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.3K Buy
2,774
+74
+3% +$543 ﹤0.01% 5014
2025
Q4 		$14.1K Buy
+2,700
New +$11.1K ﹤0.01% 5097

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

BNP Paribas Financial Markets's IMMX Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Immix Biopharma (IMMX) stake by 2.7% in Q1 2026, buying an estimated $543 and bringing the position to 2,774 shares worth $25.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5014.

BNP Paribas Financial Markets first reported a position in IMMX in Q4 2025 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • BNP Paribas Financial Markets held 2,774 shares of Immix Biopharma worth $25.3K as of Q1 2026.
  • BNP Paribas Financial Markets bought 74 Immix Biopharma shares in Q1 2026, an estimated $543.
  • Immix Biopharma made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5014 holding.
  • BNP Paribas Financial Markets first reported a position in Immix Biopharma in Q4 2025 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.